Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Feb 17 () - ‌Drug ‌developer Compass ​Pathways said on ‌Tuesday ⁠its ⁠psilocybin-based ​depression ​therapy ​met ‌the main ...